C. Selvakumar

The purpose of this study is to investigate the glycoprotein and efficacy of combination of paclitaxel along with Di allyl sulfide against skin cancer in experimental animals. Skin cancer is the most common form of human cancer. It is estimated that over 1 million new cases occur annually. The annual rates of all forms of skin cancer are increasing each year, representing a growing public concern. The most common warning sign of skin cancer is a change in the appearance of the skin, such as a new growth or a sore that will not heal. Skin cancer is caused by chemical carcinogens and Papilloma virus infection. Skin cancer was induced in rats by 7, 12 Di methyl benz(a) anthracene (DMBA) at the dosage of 5 µg was dissolved in 100µl and administered into experimental animals for 28 weeks. In this study, we demonstrated that combination of paclitaxel and Di allyl sulfide protects the rats from a lethal dose of DMBA for 30 days. The levels of glycoprotein in plasma, skin and liver were found to be increased in the cancer bearing animals when compared with control animals. Treatment of Paclitaxel along with Di allyl sulfide to cancer induced animals showed significantly decreased levels of glycoprotein levels when compared with cancer induced animals. The treatment with combination of paclitaxel and Di allyl sulfide effectively reduced glycoprotein levels. So, from the obtained results it is concluded that paclitaxel and Di allyl sulfide is capable of restoring the skin architecture. Key words: Paclitaxel, Di allyl sulfide, DMBA, Skin cancer.